<!–
Suara.com – Researcher at the Indonesian Institute of Sciences Biotechnology Research Center (LIPI) Wien Kusharyoto said the level of efficacy or efficacy of the COVID-19 vaccine 70 percent should be developed by Indonesia and then used en masse.
“Actually it is better if it is above 70 percent but from the FDA (United States Food and Drug Administration) they say that if the effectiveness is 50 percent then it can continue to the next stage,” said Wien as quoted by Antara, Monday (5/10 / 2020).
Vaccines are said to be effective if they can stimulate the body’s response to produce antibodies to fight germs such as viruses or bacteria.
According to Wien, if the level of efficacy or efficacy of the COVID-19 vaccine developed by Indonesia is above 70 percent, it can achieve population immunity or herd immunity.
“For example, 70 percent means that if the entire population is vaccinated in Indonesia, 70 percent of them just assume that they are protected, protected from their disease is enough to obtain herd immunity,” he said.
If the vaccine has been injected and the immune system is built, it is hoped that activities in the community can run more safely and productively.
Wien said that the COVID-19 vaccine that was created had to be effective, safe and did not cause side effects.
“Seventy percent means that it is effective, safe and does not cause side effects. Even if it causes side effects, you want it to be tolerated. For example, some vaccines cause dizziness, a little nausea,” he said.
Meanwhile the Minister of Research and Technology (Minister of Research and Technology) Bambang PS Brodjonegoro wanted Red and White vaccine developed must be as effective as possible to build body antibodies against the SARS-CoV-2 virus that causes COVID-19.
“The target is as effective as possible and can generate antibodies for vaccine recipients against exposure to the COVID-19 virus. Therefore, we are using virus isolates that are transmitting in Indonesia,” said Minister of Research and Technology Bambang in Jakarta, Monday.
The Red and White vaccine seeds are being developed by the Eijkman Institute for Molecular Biology using the SARS-CoV-2 virus isolate that causes COVID-19 circulating in Indonesia. The vaccine was developed on a recombinant protein subunit platform.
–
